Core Viewpoint - The U.S. District Court for the District of Delaware upheld the jury's finding of willful infringement by Alcon and awarded Sight Sciences over $34 million in past damages, along with ongoing royalties through November 2028 [1][2]. Legal Outcome - The Court's order confirmed the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents and awarded $34 million in monetary damages, which includes $5.5 million in lost profits and $28.5 million in royalty damages [2][6]. - An ongoing royalty of 10% of Hydrus revenue will be applicable until the expiration of Sight Sciences' last asserted patent on November 10, 2028 [2][6]. Company Perspective - Sight Sciences expressed satisfaction with the ruling, emphasizing the importance of its intellectual property portfolio in interventional glaucoma and its commitment to advancing glaucoma care through innovative technologies [4]. - The company anticipates recording a $5.4 million success fee related to the litigation, which will be excluded from non-GAAP adjusted operating expenses [4]. Product and Technology Focus - Sight Sciences is dedicated to developing innovative and interventional solutions for eye care, particularly in the field of glaucoma, utilizing minimally invasive techniques [5]. - The company's products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are designed to reduce intraocular pressure in patients with primary open-angle glaucoma [5].

Core Viewpoint - Sight Sciences, Inc. has achieved a significant legal victory in its patent infringement case against Alcon, with the court upholding the jury's verdict of willful infringement and awarding substantial monetary damages [1][2]. Legal Outcome - The U.S. District Court for the District of Delaware confirmed the jury's verdict that Alcon willfully infringed three patents held by Sight Sciences, resulting in a monetary award of $34 million for past infringement, along with ongoing royalties of 10% of Hydrus revenue until November 10, 2028 [2][6]. - The final judgment is pending and will include supplemental damages and interest, with the possibility of an appeal by Alcon [2][6]. Financial Implications - The past monetary damages consist of $5.5 million in lost profits and $28.5 million in royalty damages related to Hydrus sales from its launch until the jury verdict [6]. - The company anticipates recording a $5.4 million success fee to operating expenses, which will be excluded from non-GAAP adjusted operating expenses [4]. Company Overview - Sight Sciences focuses on developing innovative eyecare technologies aimed at transforming patient care, particularly in the field of glaucoma treatment [5]. - The company's product offerings include the OMNI® Surgical System and TearCare® System, which utilize minimally invasive techniques to address prevalent eye diseases [5]. Intellectual Property Strategy - The company emphasizes the importance of safeguarding its intellectual property portfolio, which includes microinvasive glaucoma implants and canaloplasty devices, to support ongoing innovation and investment in new treatment solutions [4].